Mereo BioPharma Group plc American Depositary Shares

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Soleno Therapeutics, where investors who purchased stock between March 26, 2025 and November 4, 2025 may be entitled to compensation. The lawsuit alleges Soleno made false statements about safety concerns related to its DCCR drug candi...

A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged...

Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc alleging securities fraud. The lawsuit stems from Mereo's announcement on December 29, 2025, that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, causing the stock to plummet 87.7% to $0.29 per share. Investors have until April 6, 2026, to requ...

A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged...

A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged...